 Cardiovascular Risk and Statin Eligibility of Young Adults After 
an MI:
Partners YOUNG-MI Registry
Avinainder Singh, MBBSa, Bradley L. Collins, BAa, Ankur Gupta, MD, PhDa, Amber Fatima, 
MBBSb, Arman Qamar, MDc, David Biery, BSa, Julio Baeza, Mary Cawleya, Josh Klein, BSa, 
Jon Hainer, BSa, Jorge Plutzky, MDc, Christopher P. Cannon, MDc, Khurram Nasir, MD, 
MPHd, Marcelo F. Di Carli, MDa, Deepak L. Bhatt, MD, MPHc, and Ron Blankstein, MDa
aCardiovascular Imaging Program, Departments of Medicine and Radiology, Brigham and 
Women’s Hospital, Harvard Medical School, Boston, Massachusetts
bDepartment of Medicine, Tufts Medical Center, Boston, Massachusetts
cCardiovascular Division, Department of Medicine, Brigham and Women’s Hospital, Harvard 
Medical School, Boston, Massachusetts
dMiami Cardiac and Vascular Institute, Baptist Health South Florida, Miami, Florida
Abstract
BACKGROUND—Despite significant progress in primary prevention, the rate of MI has not 
declined in young adults.
OBJECTIVES—The purpose of this study was to evaluate statin eligibility based on the 2013 
American College of Cardiology/American Heart Association guidelines for treatment of blood 
cholesterol and 2016 U.S. Preventive Services Task Force recommendations for statin use in 
primary prevention in a cohort of adults who experienced a first-time myocardial infarction (MI) at 
a young age.
METHODS—The YOUNG-MI registry is a retrospective cohort from 2 large academic centers, 
which includes patients who experienced an MI at age ≤50 years. Diagnosis of type 1 MI was 
adjudicated by study physicians. Pooled cohort risk equations were used to estimate 
atherosclerotic cardiovascular disease risk score based on data available prior to MI or at the time 
of presentation.
RESULTS—Of 1,685 patients meeting inclusion criteria, 210 (12.5%) were on statin therapy 
prior to MI and were excluded. Among the remaining 1,475 individuals, the median age was 45 
years, there were 294 (20%) women, and 846 (57%) had ST-segment elevation MI. At least 1 
cardiovascular risk factor was present in 1,225 (83%) patients. The median 10-year atherosclerotic 
cardiovascular disease risk score of the cohort was 4.8% (interquartile range: 2.8% to 8.0%). Only 
724 (49%) and 430 (29%) would have met criteria for statin eligibility per the 2013 American 
ADDRESS FOR CORRESPONDENCE: Dr. Ron Blankstein, Departments of Medicine (Cardiovascular Division) and Radiology, 
Brigham & Women’s Hospital, 75 Francis Street, Boston, Massachusetts 02115. rblankstein@bwh.harvard.edu. 
APPENDIX For supplemental figures and tables, please see the online version of this paper.
HHS Public Access
Author manuscript
J Am Coll Cardiol. Author manuscript; available in PMC 2018 March 01.
Published in final edited form as:
J Am Coll Cardiol. 2018 January 23; 71(3): 292–302. doi:10.1016/j.jacc.2017.11.007.
Author Manuscript
Author Manuscript
Author Manuscript
Author Manuscript
 College of Cardiology/American Heart Association guidelines and 2016 U.S. Preventive Services 
Task Force recommendations, respectively. This finding was even more pronounced in women, in 
whom 184 (63%) were not eligible for statins by either guideline, compared with 549 (46%) men 
(p < 0.001).
CONCLUSIONS—The vast majority of adults who present with an MI at a young age would not 
have met current guideline-based treatment thresholds for statin therapy prior to their MI. These 
findings highlight the need for better risk assessment tools among young adults.
Keywords
myocardial infarction; prevention; risk; statin; young adults
Significant progress in prevention of coronary artery disease (CAD) has led to a decrease in 
the incidence of myocardial infarction (MI) (1). However, recent reports highlight that the 
reduction in the rate of MI has not extended to young adults, and young women in particular 
continue to have worse cardiovascular outcomes than men (2,3).
Identifying individuals who are at risk for cardiovascular events is paramount, as such 
individuals can be targeted for more aggressive primary prevention efforts (4). Nevertheless, 
predicting risk in young adults is challenging, and most risk calculators fail to identify 
susceptible young adults as high risk. For instance, a prior study applied the National 
Cholesterol Education Program (NCEP) III guidelines (5) to a group of young adults with 
MI and reported that only 25% would have been eligible for statin therapy prior to their MI 
(6).
However, risk prediction has evolved considerably, and the 2013 American College of 
Cardiology/American Heart Association (ACC/AHA) guidelines for cholesterol lowering (7) 
and 2016 U.S. Preventive Services Task Force (USPSTF) recommendations for primary 
prevention statin use (8) have significantly expanded the number of individuals who are 
candidates for statin therapy (9).
The underestimation of cardiovascular risk among young individuals and the subsequent lost 
opportunity to prevent events is concerning, given the disparity in reducing the rate of MI in 
this population (3). Therefore, we sought to determine how contemporary guidelines 
perform in identifying the need for statin therapy among a cohort of men and women who 
experienced a first-time MI at a young age. In addition, within this cohort, we evaluated the 
prevalence of major cardiovascular risk factors to determine their utility in enhancing the 
identification of at-risk young individuals.
METHODS
STUDY POPULATION
The design of the YOUNG-MI registry has been previously described (10). In brief, this is a 
retrospective cohort study from 2 large academic medical centers (Brigham and Women’s 
Hospital and Massachusetts General Hospital), which included patients who experienced an 
MI at or before 50 years of age between 2000 and 2016. All records were adjudicated by a 
Singh et al.
Page 2
J Am Coll Cardiol. Author manuscript; available in PMC 2018 March 01.
Author Manuscript
Author Manuscript
Author Manuscript
Author Manuscript
 team of study physicians, as previously described (10), using the Third Universal Definition 
of MI (11). For the present analysis, only patients with type 1 MI were included. Individuals 
with known CAD (defined as prior MI or revascularization) were excluded. Individuals were 
also excluded if they had missing values for lipid profiles or systolic blood pressure, which 
are necessary components for the pooled cohort equations (PCE) for estimation of 
cardiovascular risk, and hence, determination of statin eligibility (12). Online Figure 1 
provides a consort diagram of the study population.
RISK FACTORS
The presence of cardiovascular risk factors was ascertained by a detailed review of 
electronic medical records during or before the index admission. For each risk factor, we 
also determined whether it was known prior to admission or diagnosed during 
hospitalization. Diabetes was defined as fasting plasma glucose >126 mg/dl or hemoglobin 
A1c ≥6.5% or diagnosis/treatment for diabetes. Hypertension was defined as a systolic blood 
pressure ≥140 mm Hg, diastolic blood pressure ≥90 mm Hg, or diagnosis/treatment of 
hypertension. Dyslipidemia was defined as total cholesterol ≥240 mg/dl, serum triglycerides 
≥150 mg/dl, high-density lipoprotein cholesterol <40 mg/dl in men or <50 mg/dl in women, 
or diagnosis/treatment of dyslipidemia. Obesity was defined as a body mass index ≥30 
kg/m2 or a diagnosis of obesity. Smoking was defined as current (tobacco products used 
within the last month), former, or never. Family history of premature CAD, defined as fatal 
MI, nonfatal MI, or coronary revascularization occurring before 55 years of age for first-
degree male family members and before 65 years of age for first-degree female family 
members, was captured by a thorough review of the electronic medical records, which 
included all clinic notes prior to admission, admission history and physical, discharge 
summaries, and follow-up visit notes.
ASSESSMENT OF CARDIOVASCULAR RISK
To determine whether each individual would qualify for statin therapy prior to his or her MI, 
we calculated the atherosclerotic cardiovascular disease (ASCVD) risk score based on data 
available prior to MI or at time of presentation using the PCE. For individuals younger than 
40 years of age at presentation, an age of 40 was assigned, as PCE are only applicable to 
individuals age 40 to 79 years. For those with a triglyceride level >400 mg/dl, the method 
described by Martin et al. (13) was used to estimate low-density lipoprotein (LDL) 
cholesterol, as this method has been shown to be more accurate compared with the 
Friedewald equation in such scenarios. Risk factors that were diagnosed during the index 
hospitalization for MI were not used for calculating the risk scores, as the intent of our study 
was to evaluate how many patients would have met criteria for statin therapy prior to 
presentation.
In addition to the ASCVD 10-year risk, we also estimated the lifetime cardiovascular risk 
based on the burden of traditional risk factors (14). The criteria used to define each risk 
category are provided in Online Table 1. The cohort was also divided into a low lifetime risk 
group (lifetime risk <39%) and high lifetime risk group (lifetime risk ≥39%), based on 
thresholds established in prior studies (15).
Singh et al.
Page 3
J Am Coll Cardiol. Author manuscript; available in PMC 2018 March 01.
Author Manuscript
Author Manuscript
Author Manuscript
Author Manuscript
 STATIN ELIGIBILITY
The 2013 ACC/AHA guidelines (7) and the 2016 USPSTF recommendations (8) were used 
to assess statin eligibility. Individuals were considered to be statin eligible if guidelines 
indicated that statins are recommended or statins are considered. Although our goal was to 
evaluate contemporary statin guidelines, we also assessed statin eligibility according to the 
older NCEP III guidelines (5). Specific criteria that were followed for each guideline are 
detailed in Online Table 2.
DATA MANAGEMENT
Study-related data for all patients who met inclusion criteria were stored on our customized 
secure electronic adjudication system and REDCap. REDCap is an encrypted, secure, Health 
Insurance Portability and Accountability Act–compliant web platform for electronic data 
capture and serves as an intuitive interface to enter data with real-time validation (16). The 
YOUNG-MI registry has been approved by the Institutional Review Board at Partners 
HealthCare.
STATISTICAL ANALYSIS
Categorical variables are reported as frequencies and proportions, and were compared with 
the chi-square or Fisher exact test, as appropriate. Continuous variables are reported as 
means or medians and compared with the Student’s t-test or the Mann-Whitney U test, as 
appropriate.
To determine how the ASCVD risk score or the 2013 ACC/AHA guidelines can be enhanced 
to identify more individuals prior to their MI, we reclassified all statin-ineligible individuals 
with LDL cholesterol ≥160 mg/dl or family history of premature cardiovascular disease to 
statin considered, as these criteria were offered by the guidelines as additional factors that 
may influence ASCVD risk (7).
Because most patients did not have any available data on lipid values prior to their MI, and 
because lipid levels can decrease at the time of MI, we performed 2 separate sensitivity 
analyses to determine the potential effect of using lipid values obtained at the time of MI. 
First, we performed a sensitivity analysis that only included patients who had available 
cholesterol measurements prior to their MI. Second, we performed a separate sensitivity 
analysis where we increased the total cholesterol level of all patients who did not have prior 
cholesterol values by 12%. This was based on the observed decrease in total cholesterol in 
our cohort among patients who had measurements of total cholesterol prior to their MI and 
upon admission. Because blood pressure during hospitalization for MI can be labile, we also 
performed a sensitivity analysis that only included patients who had available blood pressure 
measurements prior to their MI. A 2-sided p value <0.05 was considered significant. All 
analyses were performed using Stata version 14.2 (StataCorp, College Station, Texas).
Singh et al.
Page 4
J Am Coll Cardiol. Author manuscript; available in PMC 2018 March 01.
Author Manuscript
Author Manuscript
Author Manuscript
Author Manuscript
 RESULTS
BASELINE CHARACTERISTICS
The cohort consisted of 1,685 patients who met inclusion criteria, of whom 210 (12.5%) 
were on statin therapy prior to MI. These patients were excluded from all subsequent 
analyses. The remaining cohort consisted of 1,475 individuals with a median age of 45 
years, of whom 294 (20%) were women and 1,060 (72%) were white. There were 255 
patients (17.3%) under the age of 40 years at the time of the MI (range 19 to 39 years). 
Other baseline characteristics are provided in Table 1.
PREVALENCE AND AWARENESS OF RISK FACTORS
When examining the prevalence of risk factors, 1,225 (83%) patients had at least 1 of the 
following: diabetes, dyslipidemia, hypertension, or smoking. Dyslipidemia was the most 
common risk factor, which was present in 818 (55%) patients, followed by smoking in 772 
(52%) and hypertension in 649 (44%). Figure 1 shows the distribution of the most common 
risk factors within our cohort, stratified by the proportion of patients in whom statins are 
recommended, considered, or not recommended by the 2013 ACC/AHA guideline.
Among the patients with dyslipidemia, 163 of 818 (20%) had no prior history of this 
condition and were first diagnosed during the index hospitalization for MI. Similarly, 
diabetes and hypertension were first diagnosed in 55 of 246 (22%) and 61 of 649 (9%) 
patients, respectively. When considering the 3 major cardiovascular risk factors proposed by 
the USPSTF—namely, diabetes, dyslipidemia, and hypertension, 226 (21%) of 1,069 
patients were unaware of having at least 1 of these risk factors.
CARDIOVASCULAR RISK AND STATIN ELIGIBILITY
The median ASCVD risk score of the population was 4.8% (interquartile range: 2.8% to 
8%), with 1,068 (72%) having an ASCVD risk score of <7.5%. When considering the 
lifetime cardiovascular risk of the population, 1,184 (80.3%) were at high risk (Figure 2). 
Online Figure 2 provides detailed risk factor burden and lifetime risk estimates stratified by 
sex.
When applying the 2013 ACC/AHA guideline, only 455 (31%) would have met criteria for 
initiation of statin therapy prior to their MI, an additional 269 (18%) would have met criteria 
for consideration of statin therapy, and the remaining 751 (51%) would not have been 
eligible for primary prevention statin therapy (Central Illustration).
When applying the 2016 USPSTF recommendations, only 269 (18%) would have met 
criteria for initiating statin therapy, an additional 161 (11%) would have met criteria for 
consideration of statin therapy, and the remaining 1,045 (71%) would not have been eligible 
for statin therapy (Central Illustration).
When applying both the 2013 ACC/AHA and the 2016 USPSTF recommendations to our 
entire study population, only 742 (50%) patients would have been categorized as statin 
eligible—that is, categorized as statin recommended or statin considered by either guideline
—prior to their MI. Furthermore, 23% (52 of 226) and 43% (98 of 226) of patients with at 
Singh et al.
Page 5
J Am Coll Cardiol. Author manuscript; available in PMC 2018 March 01.
Author Manuscript
Author Manuscript
Author Manuscript
Author Manuscript
 least 3 of the following risk factors—diabetes, hypertension, dyslipidemia, and smoking—
would not have been eligible for statin therapy according to the 2013 ACC/AHA guidelines 
and 2016 USPSTF recommendations, respectively (Figure 3).
The number of patients in which the variables required for calculating the ASCVD risk score 
were available pre-presentation are provided in Online Table 3. When we increased the total 
cholesterol of all patients without prior lipid values, we observed a similar proportion 
eligible for statin therapy (56% by 2013 ACC/AHA and 34% by 2016 USPSTF) (Online 
Table 4). When we limited our analyses to patients who had available cholesterol levels prior 
to their MI, we observed that a greater proportion of these patients were eligible for statins 
compared with the overall study population (63% vs. 48% by 2013 ACC/AHA) (Online 
Table 5). This was driven by the fact that this group had more risk factors, including a higher 
prevalence of diabetes and hypertension, than those who did not have lipid values obtained 
prior to their MI (Online Table 6). When we limited our analysis to patients who had 
available blood pressure measurements prior to MI, there was no significant difference in 
statin eligibility (Online Table 7).
We also evaluated the NCEP III guidelines, according to which 347 (23%) patients would 
have met criteria for initiating statin therapy, 160 (11%) would have met criteria for 
consideration of statin therapy, and the remaining 968 (66%) would not have been eligible 
for statin therapy (Online Table 8). Figure 4 depicts the proportion of statin eligibility and 
the overlap between the 3 guidelines.
SEX DIFFERENCES
When considering the prevalence of risk factors by sex, there were significant differences. 
When compared with men, women had a lower prevalence of hyperlipidemia (30% vs. 59%; 
p < 0.001), as well as lower total cholesterol, LDL cholesterol, and triglycerides, but higher 
high-density lipoprotein cholesterol. Women also had a higher prevalence of obesity (37% 
vs. 28%; p = 0.003) and a trend toward a higher prevalence of smoking (57% vs. 51%; p = 
0.068). The median ASCVD risk score was significantly lower in women (3.2 vs. 5.2; p < 
0.001), and 244 (83%) women had an ASCVD score of <7.5% compared with 824 (70%) 
men (p < 0.001) (Table 2).
When applying the 2013 ACC/AHA guidelines, over 64% of women would not have been 
eligible for statin therapy compared with 49% of men (p < 0.001) (Figure 5). When applying 
the USPSTF recommendations, 82% of women would not have been eligible compared with 
68% of men (p = 0.002). Overall, only 37% of women would have been eligible for statin 
therapy by either the 2013 ACC/AHA or USPSTF guidelines compared with 54% of men (p 
< 0.001) (Table 2).
ENHANCEMENT OF STATIN ELIGIBILITY
We estimated the effect of modifying the risk prediction and incorporating additional risk 
factors to increase statin eligibility; these are provided in the Online Appendix and Online 
Figure 3.
Singh et al.
Page 6
J Am Coll Cardiol. Author manuscript; available in PMC 2018 March 01.
Author Manuscript
Author Manuscript
Author Manuscript
Author Manuscript
 DISCUSSION
To the best of our knowledge, this study is the first to apply the 2013 ACC/AHA cholesterol 
guidelines and 2016 USPSTF primary prevention recommendations for statin therapy to a 
large cohort of adults who experienced an MI at a young age, and is 1 of the largest to look 
at distributions of risk factors prior to MI among adults under the age of 50 years. We found 
that despite the expanded use of statins advocated by these recommendations (9,17), current 
guidelines did not identify most young adults who experienced an MI to be eligible for 
statins at the time of or prior to their event. In our study, 51% of subjects would not have 
been eligible for statin therapy prior to their MI if the 2013 ACC/AHA guidelines were 
implemented, and 71% would not have been eligible by the 2016 USPSTF 
recommendations. Our findings were more striking in women, where only 36% and 18% 
were determined to be eligible by the 2013 ACC/AHA guidelines and 2016 USPSTF 
recommendations, respectively. It is notable that the underestimation of risk in this cohort 
exists despite the high prevalence of traditional cardiovascular risk factors (with 4 of every 5 
patients having at least 1 major cardiovascular risk factor). Furthermore, in calculating the 
ASCVD risk score, we conservatively increased the minimum age to 40 years, and 
reclassified all patients in the statin considered category (i.e., ASCVD risk score of 5% to 
7.5%) as statin eligible, as has been suggested by others as a method for improving the 
applicability of these criteria to young adults (18).
RISK PREDICTION IN YOUNG ADULTS
In 2002, Akosah et al. (6) evaluated the statin eligibility of 222 “young adults” (men age ≤55 
years and women age ≤65 years) hospitalized for MI using the then current NCEP III 
guidelines, and found that 82% of women and 59% of men did not meet thresholds for 
pharmacotherapy prior to their MI, despite a high prevalence of cardiovascular risk factors, 
particularly among women. The authors concluded that there is a need for better risk 
prediction in young adults. Although various guidelines have subsequently been developed, 
no studies have been performed applying the various proposed criteria to young adults. 
When applied to other populations, the ASCVD risk calculator based on the PCE has been 
shown to overestimate risk (19–21); however, our findings suggest that this risk score, which 
is highly dependent on age (19,22), also has the potential to underestimate risk in younger 
individuals. Although the 2016 USPSTF recommendations and 2001 NCEP III guidelines 
each identify a small proportion of individuals that was not eligible by 2013 ACC/AHA 
guidelines, even when considering patients who may be eligible by any of the 3 guidelines, a 
significant proportion of at-risk population would not have been categorized as statin eligible 
(Figure 4).
OPPORTUNITIES FOR ENHANCING RISK PREDICTION
In the current era of generic statins that are generally well tolerated, several mechanisms 
have been suggested for better identification of more at-risk individuals. For instance, Navar-
Boggan et al. (18) suggested that decreasing the treatment threshold to include the statin-
considered group (i.e., ASCVD risk score of 5% to 7.5%) would improve the sensitivity of 
identifying individuals who ultimately experienced cardiovascular events. In our cohort, this 
increased statin eligibility by 18% for the ACC/AHA guideline. In addition to performing 
Singh et al.
Page 7
J Am Coll Cardiol. Author manuscript; available in PMC 2018 March 01.
Author Manuscript
Author Manuscript
Author Manuscript
Author Manuscript
 these measures, we also evaluated how including other risk factors proposed by the 2013 
ACC/AHA statin guidelines may further enhance risk prediction. Specifically, we found that 
reclassifying all patients with LDL cholesterol >160 mg/dl and a family history of premature 
CAD as statin eligible would increase the proportion of treated patients from 49% to 66%. 
However, any criteria that would identify more at-risk individuals would lead to a higher 
proportion of treated patients across the population who would not necessarily experience 
events. Thus, although our findings suggest that incorporating the previously mentioned risk 
factors in making decisions regarding the role of statins in young individuals may be 
important, future investigations should further elucidate the population-level effect of such 
approaches aimed at expanding the number of individuals treated.
Any effort to expand the number of treated young individuals should also incorporate the 
following considerations: 1) although no randomized studies have assessed the role of statins 
for primary prevention among young adults, Mendelian randomization studies suggest that a 
longer exposure to low LDL cholesterol may provide long-term benefits (23); 2) although 
the overall risk of most young patients is low, younger individuals represent the largest 
proportion of the population who are at risk (24); and 3) patients who experience an MI at a 
younger age have a larger economic impact, as their lifetime earnings and societal 
contributions are affected to a greater extent. Ultimately, in the absence of randomized data 
(25), and given the need to balance the risks and benefits of treatment together with patients’ 
disutility from being on statin therapy, there is an important need to incorporate shared 
decision making between patients and physicians (26).
In addition to the aforementioned efforts in identifying at-risk patients, our study also 
reinforces the need for more primordial prevention (27–29). In fact, >80% of the patients 
who had an MI at a young age had at least 1 modifiable risk factor, with dyslipidemia, 
smoking, and hypertension being the most prevalent. The USPSTF has established 
guidelines for screening for traditional cardiovascular risk factors in adults, and current 
recommendations include: screening for hypertension annually in patients age ≥40 years, 
and every 3 to 5 years in patients 18 to 40 years of age (30); screening overweight or obese 
adults age 40 to 70 years for diabetes (31); and providing pharmacotherapy or behavioral 
interventions to adults for smoking cessation (32). The USPSTF recommends screening for 
dyslipidemia every 5 years in patients age ≥40 years, but was neither for nor against 
screening patients age 21 to 39 years, citing lack of evidence in this age group (8). The 2013 
ACC/AHA cholesterol guidelines have expanded the number of individuals eligible for 
statin therapy, and accordingly, recent data suggests that there has been a gradual but 
sustained increase in statin use for primary preventions (33).
SEX DIFFERENCES IN STATIN ELIGIBILITY
Women had significantly lower statin eligibility compared with men, even though there were 
no significant differences in age or the burden of risk factors between men and women. 
Although the more pronounced underestimation of risk in women in our cohort cannot be 
explained by differences in age or risk factors alone, it is noteworthy that the PCE has been 
shown to overestimate risk in women (34). Further research is required to better identify risk 
Singh et al.
Page 8
J Am Coll Cardiol. Author manuscript; available in PMC 2018 March 01.
Author Manuscript
Author Manuscript
Author Manuscript
Author Manuscript
 and prevent cardiovascular disease in women, particularly as women have worse outcomes 
post-MI compared with similarly aged men (35).
STUDY LIMITATIONS
Our study is retrospective in nature and thus subject to limitations regarding uniformity of 
data collection. However, our retrospective cohort design is ideal for studying less frequent 
conditions, such as MI in young individuals. In addition, we performed a manual review of 
all admission notes, rather than rely on billing or other coded information, to both adjudicate 
the presence of MI as well as determine the prevalence of various risk factors. Although our 
findings reinforce the need for better identification of risk among young individuals, a 
limitation of our study is that we only evaluated individuals who experienced an MI, without 
considering the overall at-risk population for this age group. As a result, we were not able to 
determine the prevalence of various risk factors across the population of at-risk patients who 
did not experience an MI, as has previously been done by other population-based cohorts 
(36). In the future, the use of machine learning algorithms may facilitate other study designs, 
such as retrospective case-control studies, which may provide further information in this 
regard.
Lipid levels may be falsely lowered at the time of MI; however, one of the largest studies 
examining this did not find a clinically meaningful change (37). Nevertheless, we analyzed 
the change in total cholesterol for patients who had available measurements before their MI 
and during the index admission. In these patients, the total cholesterol decreased by 12%. 
Consequently, we performed a sensitivity analysis by increasing the total cholesterol of all 
patients who did not have prior cholesterol values by 12%, and our findings remained robust, 
suggesting that any potential changes in lipid values peri-MI did not have a significant effect 
on our findings.
Guidelines recommend considering factors such as high-sensitivity C-reactive protein, 
coronary artery calcium, and ankle brachial pressure index, but results from such testing 
were not available for our cohort. Finally, our risk estimates may be too conservative, as we 
increased the age of some of the patients by more than 10 years, and it is likely that we 
would have observed an even higher proportion of patients who were not statin eligible if we 
used actual age in calculating the ASCVD risk score from PCE. However, the PCE are 
derived from and thereby applicable only to those who are 40 to 79 years of age (12).
Despite the fact that this study was conducted across 2 large academic medical centers, our 
results remain generalizable to other settings, as our study examines baseline risk level and 
is not related to the treatment received. Although there may be geographical differences in 
some cardiovascular risk factors, these are unlikely to influence our main results, as our 
population had a high prevalence of underlying risk factors, and it was their younger age, 
rather than failure to capture these risk factors, that contributed to them being classified as 
statin ineligible. Our study population was mostly white, and we recognize that certain 
groups such as South Asians may have a higher predisposition to develop premature CAD, 
and risk scores may further underestimate their risk (38–40); however, we did not have 
sufficient power to analyze subgroups based on race or ethnicity.
Singh et al.
Page 9
J Am Coll Cardiol. Author manuscript; available in PMC 2018 March 01.
Author Manuscript
Author Manuscript
Author Manuscript
Author Manuscript
 CONCLUSIONS
The vast majority of adults who present with an MI at a young age would not have met 
current guideline-based treatment thresholds for statin therapy prior to their MI. These 
findings highlight the need to develop better risk assessment tools among young adults.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
Dr. Gupta is supported by National Institutes of Health grant number 5T32HL094301. Dr. Qamar is supported by 
National Institutes of Health grant number T32HL007604. Dr. Bhatt has served on Advisory Board of Cardax, 
Elsevier Practice Update Cardiology, Medscape Cardiology, and Regado Biosciences; has served on the Board of 
Directors of Boston VA Research Institute and the Society of Cardiovascular Patient Care; is Chair of the American 
Heart Association Quality Oversight Committee; has served on Data Monitoring Committees for Cleveland Clinic, 
Duke Clinical Research Institute, Harvard Clinical Research Institute, Mayo Clinic, Mount Sinai School of 
Medicine, and Population Health Research Institute; has received honoraria from American College of Cardiology 
(Senior Associate Editor, Clinical Trials and News, ACC.org), Belvoir Publications (Editor-in-Chief, Harvard Heart 
Letter), HMP Communications (Editor-in-Chief, Journal of Invasive Cardiology), Journal of the American College 
of Cardiology (Guest Editor; Associate Editor), Slack Publications (Chief Medical Editor, Cardiology Today’s 
Intervention), Society of Cardiovascular Patient Care (Secretary/Treasurer), and WebMD (CME steering 
committees); has received honoraria for serving on clinical trial steering committees of Duke Clinical Research 
Institute, Harvard Clinical Research Institute, and Population Health Research Institute; has served as Deputy 
Editor of Clinical Cardiology; has served as chair of the NCDR-ACTION Registry Steering Committee and VA 
CART Research and Publications Committee; has received research funding from Amarin, Amgen, AstraZeneca, 
Bristol-Myers Squibb, Chiesi, Eisai, Ethicon, Forest Laboratories, Ironwood, Ischemix, Lilly, Medtronic, Pfizer, 
Roche, Sanofi, and The Medicines Company; has received royalties from Elsevier (Editor, Cardiovascular 
Intervention: A Companion to Braunwald’s Heart Disease); has served as site coinvestigator for Biotronik, Boston 
Scientific, and St. Jude Medical (now Abbott); has served as a trustee of American College of Cardiology; and has 
performed unfunded research for FlowCo, Merck, PLx Pharma, and Takeda. Dr. Blankstein has served on the 
advisory board of Amgen; and has received research support from Amgen and Gilead Sciences. All other authors 
have reported that they have no relationships relevant to the contents of this paper to disclose. This paper was 
presented on November 14, 2017, at the Ancel Keys Cardiovascular Disease Prevention Session, American Heart 
Association 2017 Scientific Sessions, Anaheim, California.
ABBREVIATIONS AND ACRONYMS
ASCVD
atherosclerotic cardiovascular disease
CAD
coronary artery disease
LDL
low-density lipoprotein
MI
myocardial infarction
NCEP
National Cholesterol Education Panel
PCE
pooled cohort equations
USPSTF
U.S. Preventive Services Task Force
References
1. Eisen A, Giugliano RP, Braunwald E. Updates on acute coronary syndrome: a review. JAMA 
Cardiol. 2016; 1:718–30. [PubMed: 27438381] 
Singh et al.
Page 10
J Am Coll Cardiol. Author manuscript; available in PMC 2018 March 01.
Author Manuscript
Author Manuscript
Author Manuscript
Author Manuscript
 2. Bucholz EM, Strait KM, Dreyer RP, et al. Sex differences in young patients with acute myocardial 
infarction: a VIRGO study analysis. Eur Heart J Acute Cardiovasc Care. 2017; 6:610–22. [PubMed: 
27485141] 
3. Gupta A, Wang Y, Spertus JA, et al. Trends in acute myocardial infarction in young patients and 
differences by sex and race, 2001 to 2010. J Am Coll Cardiol. 2014; 64:337–45. [PubMed: 
25060366] 
4. Gidding SS. Why cholesterol testing in children and adolescents matters. JAMA Cardiol. 2016; 
1:859–61. [PubMed: 27548876] 
5. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. 
Executive summary of the Third Report of The National Cholesterol Education Program (NCEP) 
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult 
Treatment Panel III). JAMA. 2001; 285:2486–97. [PubMed: 11368702] 
6. Akosah KO, Schaper A, Cogbill C, Schoenfeld P. Preventing myocardial infarction in the young 
adult in the first place: how do the National Cholesterol Education Panel III guidelines perform? J 
Am Coll Cardiol. 2003; 41:1475–9. [PubMed: 12742284] 
7. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood 
cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College 
of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 
2014; 63:2889–934. [PubMed: 24239923] 
8. Bibbins-Domingo K, Grossman DC, et al. Force USPST. Statin use for the primary prevention of 
cardiovascular disease in adults: US Preventive Services Task Force Recommendation Statement. 
JAMA. 2016; 316:1997–2007. [PubMed: 27838723] 
9. Miedema MD, Garberich RF, Schnaidt LJ, et al. Statin eligibility and outpatient care prior to ST-
segment elevation myocardial infarction. J Am Heart Assoc. 2017; 6:e005333. [PubMed: 28404560] 
10. Singh A, Collins B, Qamar A, et al. Study of young patients with myocardial infarction: design and 
rationale of the YOUNG-MI Registry. Clin Cardiol. 2017 Aug 14. E-pub ahead of print. 
11. Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. J Am 
Coll Cardiol. 2012; 60:1581–98. [PubMed: 22958960] 
12. Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of 
cardiovascular risk: a report of the American College of Cardiology/American Heart Association 
Task Force on Practice Guidelines. J Am Coll Cardiol. 2014; 63:2935–59. [PubMed: 24239921] 
13. Martin SS, Blaha MJ, Elshazly MB, et al. Comparison of a novel method vs the Friedewald 
equation for estimating low-density lipoprotein cholesterol levels from the standard lipid profile. 
JAMA. 2013; 310:2061–8. [PubMed: 24240933] 
14. Lloyd-Jones DM, Leip EP, Larson MG, et al. Prediction of lifetime risk for cardiovascular disease 
by risk factor burden at 50 years of age. Circulation. 2006; 113:791–8. [PubMed: 16461820] 
15. Berry JD, Liu K, Folsom AR, et al. Prevalence and progression of subclinical atherosclerosis in 
younger adults with low short-term but high lifetime estimated risk for cardiovascular disease: the 
Coronary Artery Risk Development in Young Adults Study and Multi-Ethnic Study of 
Atherosclerosis. Circulation. 2009; 119:382–9. [PubMed: 19139385] 
16. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture 
(REDCap)—a metadata-driven methodology and workflow process for providing translational 
research informatics support. J Biomed Informat. 2009; 42:377–81.
17. Pencina MJ, Navar-Boggan AM, D’Agostino RB Sr, et al. Application of new cholesterol 
guidelines to a population-based sample. N Engl J Med. 2014; 370:1422–31. [PubMed: 24645848] 
18. Navar-Boggan AM, Peterson ED, D’Agostino RB Sr, Pencina MJ, Sniderman AD. Using age- and 
sex-specific risk thresholds to guide statin therapy: one size may not fit all. J Am Coll Cardiol. 
2015; 65:1633–9. [PubMed: 25743624] 
19. DeFilippis AP, Young R, McEvoy JW, et al. Risk score overestimation: the impact of individual 
cardiovascular risk factors and preventive therapies on the performance of the American Heart 
Association-American College of Cardiology-Atherosclerotic Cardiovascular Disease risk score in 
a modern multi-ethnic cohort. Eur Heart J. 2017; 38:598–608. [PubMed: 27436865] 
20. Ridker PM, Cook NR. Statins: new American guidelines for prevention of cardiovascular disease. 
Lancet. 2013; 382:1762–5. [PubMed: 24268611] 
Singh et al.
Page 11
J Am Coll Cardiol. Author manuscript; available in PMC 2018 March 01.
Author Manuscript
Author Manuscript
Author Manuscript
Author Manuscript
 21. Miedema MD, Lopez FL, Blaha MJ, et al. Eligibility for statin therapy according to new 
cholesterol guidelines and prevalent use of medication to lower lipid levels in an older US Cohort: 
the Atherosclerosis Risk In Communities study cohort. JAMA Intern Med. 2015; 175:138–40. 
[PubMed: 25401375] 
22. Karmali KN, Goff DC Jr, Ning H, Lloyd-Jones DM. A systematic examination of the 2013 
ACC/AHA pooled cohort risk assessment tool for atherosclerotic cardiovascular disease. J Am 
Coll Cardiol. 2014; 64:959–68. [PubMed: 25190228] 
23. Ference BA, Majeed F, Penumetcha R, Flack JM, Brook RD. Effect of naturally random allocation 
to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by 
polymorphisms in NPC1L1, HMGCR, or both: a 2 × 2 factorial Mendelian randomization study. J 
Am Coll Cardiol. 2015; 65:1552–61. [PubMed: 25770315] 
24. Sniderman AD, Thanassoulis G, Williams K, Pencina M. Risk of premature cardiovascular disease 
vs the number of premature cardiovascular events. JAMA Cardiol. 2016; 1:492–4. [PubMed: 
27438330] 
25. Domanski MJ, Fuster V, Diaz-Mitoma F, et al. Next steps in primary prevention of coronary heart 
disease: rationale for and design of the ECAD trial. J Am Coll Cardiol. 2015; 66:1828–36. 
[PubMed: 26483108] 
26. Krumholz HM. Treatment of cholesterol in 2017. JAMA. 2017; 318:417–8. [PubMed: 28738130] 
27. Fuster V. Stratified approach to health: integration of science and education at the right time for 
each individual. J Am Coll Cardiol. 2015; 66:1627–9. [PubMed: 26429088] 
28. Vaduganathan M, Venkataramani AS, Bhatt DL. Moving toward global primordial prevention in 
cardiovascular disease: the heart of the matter. J Am Coll Cardiol. 2015; 66:1535–7. [PubMed: 
26429076] 
29. Lloyd-Jones DM, Hong Y, Labarthe D, et al. Defining and setting national goals for cardiovascular 
health promotion and disease reduction: the American Heart Association’s Strategic Impact Goal 
through 2020 and beyond. Circulation. 2010; 121:586–613. [PubMed: 20089546] 
30. Siu AL. for the U S. Preventive Services Task Force. Screening for high blood pressure in adults: 
U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2015; 163:778–
86. [PubMed: 26458123] 
31. Siu AL. for the U S. Preventive Services Task Force. Screening for abnormal blood glucose and 
type 2 diabetes mellitus: U.S. Preventive Services Task Force Recommendation Statement. Ann 
Intern Med. 2015; 163:861–8. [PubMed: 26501513] 
32. Siu AL. for the U S. Preventive Services Task Force. Behavioral and pharmacotherapy 
interventions for tobacco smoking cessation in adults, including pregnant women: U.S. Preventive 
Services Task Force Recommendation Statement. Ann Intern Med. 2015; 163:622–34. [PubMed: 
26389730] 
33. Olufade T, Zhou S, Anzalone D, et al. Initiation patterns of statins in the 2 years after release of the 
2013 American College of Cardiology/American Heart Association (ACC/AHA) Cholesterol 
Management Guideline in a large US health plan. J Am Heart Assoc. 2017; 6:e005205. [PubMed: 
28473405] 
34. Cook NR, Ridker PM. Further insight into the cardiovascular risk calculator: the roles of statins, 
revascularizations, and underascertainment in the Women’s Health Study. JAMA Intern Med. 
2014; 174:1964–71. [PubMed: 25285455] 
35. Bangalore S, Fonarow GC, Peterson ED, et al. Age and gender differences in quality of care and 
outcomes for patients with ST-segment elevation myocardial infarction. Am J Med. 2012; 
125:1000–9. [PubMed: 22748404] 
36. Patel KK, Taksler GB, Hu B, Rothberg MB. Prevalence of elevated cardiovascular risks in young 
adults: a cross-sectional analysis of National Health and Nutrition Examination Surveys. Ann 
Intern Med. 2017; 166:876–82. [PubMed: 28505660] 
37. Pitt B, Loscalzo J, Ycas J, Raichlen JS. Lipid levels after acute coronary syndromes. J Am Coll 
Cardiol. 2008; 51:1440–5. [PubMed: 18402897] 
38. Palaniappan L, Wang Y, Fortmann SP. Coronary heart disease mortality for six ethnic groups in 
California, 1990–2000. Ann Epidemiol. 2004; 14:499–506. [PubMed: 15310526] 
Singh et al.
Page 12
J Am Coll Cardiol. Author manuscript; available in PMC 2018 March 01.
Author Manuscript
Author Manuscript
Author Manuscript
Author Manuscript
 39. Kanjilal S, Rao VS, Mukherjee M, et al. Application of cardiovascular disease risk prediction 
models and the relevance of novel biomarkers to risk stratification in Asian Indians. Vasc Health 
Risk Manag. 2008; 4:199–211. [PubMed: 18629375] 
40. Kandula NR, Kanaya AM, Liu K, et al. Association of 10-year and lifetime predicted 
cardiovascular disease risk with subclinical atherosclerosis in South Asians: findings from the 
Mediators of Atherosclerosis in South Asians Living in America (MASALA) study. J Am Heart 
Assoc. 2014; 3:e001117. [PubMed: 25277669] 
Singh et al.
Page 13
J Am Coll Cardiol. Author manuscript; available in PMC 2018 March 01.
Author Manuscript
Author Manuscript
Author Manuscript
Author Manuscript
 PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE
Most patients presenting with MI before age 50 years would not have met current 
guideline-based treatment thresholds for statin therapy prior to their event.
COMPETENCY IN PATIENT CARE AND PROCEDURAL SKILLS
Low ASCVD risk scores may be falsely reassuring in patients younger than 50 years of 
age, leading to under-treatment in certain clinical situations. In addition to the risk score, 
additional factors such as a family history of premature CAD or clustering of risk factors, 
should be considered in determining the potential benefit of statin therapy.
TRANSLATIONAL OUTLOOK
Further research is needed to optimally estimate cardiovascular risk in young adults.
Singh et al.
Page 14
J Am Coll Cardiol. Author manuscript; available in PMC 2018 March 01.
Author Manuscript
Author Manuscript
Author Manuscript
Author Manuscript
 FIGURE 1. Prevalence of Cardiovascular Risk Factors Stratified by Statin Eligibility
Distribution of the most common risk factors within our cohort, stratified by the proportion 
of patients who are recommended (blue), considered (gray), or not recommended (orange) 
to use statins by the 2013 American College of Cardiology/American Heart Association 
guidelines. CAD = coronary artery disease.
Singh et al.
Page 15
J Am Coll Cardiol. Author manuscript; available in PMC 2018 March 01.
Author Manuscript
Author Manuscript
Author Manuscript
Author Manuscript
 FIGURE 2. Lifetime Cardiovascular Risk
Proportion of patients with high lifetime cardiovascular risk (≥39%) among young adults 
with myocardial infarction.
Singh et al.
Page 16
J Am Coll Cardiol. Author manuscript; available in PMC 2018 March 01.
Author Manuscript
Author Manuscript
Author Manuscript
Author Manuscript
 FIGURE 3. Burden of Risk Factors and Statin Ineligibility
Proportion of patients not eligible for statin therapy stratified by cumulative burden of 
cardiovascular risk factors by 2013 ACC/AHA (blue) and 2016 USPSTF (orange) 
recommendations. *Cardiovascular risk factors considered include diabetes, hypertension, 
dyslipidemia, and smoking. ACC/AHA = American College of Cardiology/American Heart 
Association; USPSTF = U.S. Preventive Services Task Force.
Singh et al.
Page 17
J Am Coll Cardiol. Author manuscript; available in PMC 2018 March 01.
Author Manuscript
Author Manuscript
Author Manuscript
Author Manuscript
 FIGURE 4. Statin Eligibility of Young Adults Prior to Myocardial Infarction by Various 
Guidelines
The square represents the total population (n = 1,475) of patients who experienced a 
myocardial infarction at a young age. The colored circles represent the proportion of statin 
eligible (statins considered/statin recommended) individuals. The size is directly 
proportional to magnitude of statin eligibility, with the 2013 ACC/AHA guidelines (blue), 
2016 USPSTF recommendations (orange), and NCEP III guidelines (gray). Overlap 
between circles represents individuals that were eligible by multiple respective guidelines. 
NCEP = National Cholesterol Education Panel; other abbreviations as in Figure 3.
Singh et al.
Page 18
J Am Coll Cardiol. Author manuscript; available in PMC 2018 March 01.
Author Manuscript
Author Manuscript
Author Manuscript
Author Manuscript
 FIGURE 5. Sex Differences in Statin Eligibility
Classification of statin eligibility by the 2013 ACC/AHA guidelines (blue) and 2016 
USPSTF recommendations (orange) for women (left) and men (right). Abbreviations as in 
Figure 3.
Singh et al.
Page 19
J Am Coll Cardiol. Author manuscript; available in PMC 2018 March 01.
Author Manuscript
Author Manuscript
Author Manuscript
Author Manuscript
 CENTRAL ILLUSTRATION. Guideline-Based Statin Eligibility of Young Adults Prior to MI
Contemporary statin guidelines were applied to 1,475 young adults not on statins prior to 
myocardial infarction. (Left) The stepwise implementation of the 2013 American College of 
Cardiology/American Heart Association cholesterol guidelines. (Right) The stepwise 
implementation of the 2016 United States Preventive Services Task Force statin 
recommendations. The cohort is stratified by statin eligibility according to specified 
guideline criteria into 3 groups: statin recommended (green), statin considered (gray), and 
statin not recommended (orange). The risk factors considered by USPSTF guidelines 
include diabetes, hypertension, dyslipidemia, and smoking. ACC/AHA = American College 
of Cardiology/American Heart Association; ASCVD = atherosclerotic cardiovascular 
disease; CV = cardiovascular; LDL = low-density lipoprotein; MI = myocardial infarction; 
USPSTF = U.S. Preventive Services Task Force.
Singh et al.
Page 20
J Am Coll Cardiol. Author manuscript; available in PMC 2018 March 01.
Author Manuscript
Author Manuscript
Author Manuscript
Author Manuscript
 Author Manuscript
Author Manuscript
Author Manuscript
Author Manuscript
Singh et al.
Page 21
TABLE 1
Baseline Characteristics (N = 1,475)
Age at time of MI, yrs
45 (41–48)
Female
294 (19.9)
White
1,060 (71.9)
ST-segment elevation myocardial infarction
846 (57.4)
Diabetes
246 (16.7)
Hypertension
649 (44.0)
Dyslipidemia
818 (55.5)
Current smoking
772 (52.3)
Former smoker
196 (13.2)
Premature CAD in first-degree relative
424 (28.7)
Obesity
437 (29.6)
Total cholesterol, mg/dl
191.3 ± 55.9
HDL cholesterol, mg/dl
37.0 ± 10.6
LDL cholesterol, mg/dl
118.4 ± 45.9
Triglycerides, mg/dl
145 (101–17)
ASCVD score
4.8 (2.8–8.0)
ASCVD risk score
 <5%
770 (52.2)
 5–7.5%
298 (20.2)
 7.5–20%
365 (24.7)
 >20%
42 (2.8)
Recommended/considered for statin therapy by 2013 ACC/AHA
724 (49.1)
Recommended/considered for statin therapy by 2016 USPSTF
430 (29.2)
Recommended/considered for statin therapy by either guideline
742 (50.3)
Recommended/considered for statin therapy by NCEP III
507 (34.4)
Values are median (interquartile range), n (%), or mean ± SD.
ACC/AHA = American College of Cardiology/American Heart Association; ASCVD = atherosclerotic cardiovascular disease; CAD = coronary 
artery disease; HDL = high-density lipoprotein; LDL = low-density lipoprotein; MI = myocardial infarction; NCEP = National Cholesterol 
Education Panel; USPSTF = U.S. Preventive Services Task Force.
J Am Coll Cardiol. Author manuscript; available in PMC 2018 March 01.
 Author Manuscript
Author Manuscript
Author Manuscript
Author Manuscript
Singh et al.
Page 22
TABLE 2
Sex Differences
Male (n = 1,181, 80%)
Female (n = 294, 20%)
p Value
Age at time of MI, yrs
45 (41–48)
46 (42–48)
0.24
White
856 (72.5)
204 (69.4)
0.31
Diabetes
190 (16.1)
56 (19.0)
0.22
Hypertension
517 (43.8)
132 (44.9)
0.74
Hyperlipidemia
702 (59.4)
116 (39.5)
<0.001
Current smoking
604 (51.1)
168 (57.1)
0.068
Former smoker
167 (28.9)
29 (23.0)
0.19
Premature CAD in first-degree relative
334 (28.3)
90 (30.6)
0.43
Obesity
329 (27.9)
108 (36.7)
0.003
Total cholesterol, mg/dl
193.1 ± 57.0
184.1 ± 50.9
0.014
HDL cholesterol, mg/dl
36.1 ± 9.5
40.9 ± 13.8
<0.001
LDL cholesterol, mg/dl
119.8 ± 45.9
112.8 ± 45.6
0.02
Triglycerides, mg/dl
153 (104–230)
122 (86–177)
<0.001
ASCVD score
5.2 (3.2–8.5)
3.2 (1.2–6.0)
<0.001
ASCVD risk group
 <5%
571 (48.3)
199 (67.7)
<0.001
 5.0–7.5%
253 (21.4)
45 (15.3)
 7.5–20.0%
326 (27.6)
39 (13.3)
 >20%
31 (2.6)
11 (3.7)
Recommended/considered for statin therapy by 2013 ACC/AHA
603 (51.1)
102 (34.7)
<0.001
Recommended/considered for statin therapy by 2016 USPSTF
377 (31.9)
53 (18.0)
<0.001
Recommended/considered for statin therapy by either guideline
632 (53.5)
110 (37.4)
<0.001
Recommended/considered for statin therapy by NCEP III guidelines
378 (32.0)
129 (43.9)
<0.001
Values are median (interquartile range), n (%), or mean ± SD.
Abbreviations as in Table 1.
J Am Coll Cardiol. Author manuscript; available in PMC 2018 March 01.
